Skip to main content

Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.

Publication ,  Journal Article
Vaidyanathan, G; Affleck, DJ; Alston, KL; Welsh, P; Zalutsky, MR
Published in: Nucl Med Commun
September 2004

BACKGROUND: A fluorine substituted derivative of meta-iodobenzylguanidine (MIBG), 4-fluoro-3-iodobenzylguanidine (FIBG), is retained in SK-N-SH human neuroblastoma cells in vitro to a higher degree than the MIBG. METHOD: To investigate whether the higher retention of FIBG is due to differences in the catabolic degradation of the two tracers, in vitro paired-label studies were performed using SK-N-SH cells. RESULTS: No detectable amount of benzyl amines, benzoic acids or hippuran derivatives, potential catabolites of these tracers, were seen in either case. Even after 48 h, the cell culture supernatants contained exclusively intact I-MIBG and I-FIBG. In contrast, in some cases, HPLC analysis of cell lysates indicated the presence of a very polar compound(s) as the predominant species with smaller quantities of intact tracers. The per cent total radioactivity in the lysate at each time point that was associated with intact I-FIBG was (average [range]) 25.4% [20.3-30.5], 22.5% [19.3-25.6], and 18.8% [14.3-23.3], at 0 h, 24 h and 48 h, respectively. The corresponding values for I-MIBG were 24.3% [21.0-27.5], 19.1% [11.7-26.5] and 17.4% [14.6-20.1]. No significant amount of activity was associated with high molecular weight species for either halobenzylguanidine, indicating that protein binding was not a major factor.

Duke Scholars

Published In

Nucl Med Commun

DOI

ISSN

0143-3636

Publication Date

September 2004

Volume

25

Issue

9

Start / End Page

947 / 955

Location

England

Related Subject Headings

  • Sensitivity and Specificity
  • Reproducibility of Results
  • Radiopharmaceuticals
  • Radionuclide Imaging
  • Nuclear Medicine & Medical Imaging
  • Neuroblastoma
  • Metabolic Clearance Rate
  • Iodobenzenes
  • Humans
  • Cell Line, Tumor
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vaidyanathan, G., Affleck, D. J., Alston, K. L., Welsh, P., & Zalutsky, M. R. (2004). Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. Nucl Med Commun, 25(9), 947–955. https://doi.org/10.1097/00006231-200409000-00013
Vaidyanathan, Ganesan, Donna J. Affleck, Kevin L. Alston, Philip Welsh, and Michael R. Zalutsky. “Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.Nucl Med Commun 25, no. 9 (September 2004): 947–55. https://doi.org/10.1097/00006231-200409000-00013.
Vaidyanathan G, Affleck DJ, Alston KL, Welsh P, Zalutsky MR. Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. Nucl Med Commun. 2004 Sep;25(9):947–55.
Vaidyanathan, Ganesan, et al. “Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.Nucl Med Commun, vol. 25, no. 9, Sept. 2004, pp. 947–55. Pubmed, doi:10.1097/00006231-200409000-00013.
Vaidyanathan G, Affleck DJ, Alston KL, Welsh P, Zalutsky MR. Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells. Nucl Med Commun. 2004 Sep;25(9):947–955.

Published In

Nucl Med Commun

DOI

ISSN

0143-3636

Publication Date

September 2004

Volume

25

Issue

9

Start / End Page

947 / 955

Location

England

Related Subject Headings

  • Sensitivity and Specificity
  • Reproducibility of Results
  • Radiopharmaceuticals
  • Radionuclide Imaging
  • Nuclear Medicine & Medical Imaging
  • Neuroblastoma
  • Metabolic Clearance Rate
  • Iodobenzenes
  • Humans
  • Cell Line, Tumor